Last reviewed 2026-04-22 · How we verify

BAY3723113

BAY3723113 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma and other cancers.

BAY3723113 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma and other cancers. Used for Hepatocellular carcinoma (HCC), FGFR4-positive or FGF19-positive.

At a glance

Mechanism of action

FGFR4 is frequently activated in hepatocellular carcinoma through FGF19 autocrine signaling, driving tumor growth and survival. By selectively inhibiting FGFR4 kinase activity, BAY3723113 disrupts this oncogenic pathway. This selective approach aims to minimize off-target effects associated with pan-FGFR inhibitors while maintaining efficacy against FGFR4-dependent tumors.

Approved indications

• Hepatocellular carcinoma (HCC), FGFR4-positive or FGF19-positive

Common side effects

• Diarrhea
• Fatigue
• Nausea
• Hyperphosphatemia
• Abdominal pain

Key clinical trials

• A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.